Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regentis Biomaterials's Enterprise Value is $23.02 Mil.
Regentis Biomaterials's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.32 Mil. Therefore, Regentis Biomaterials's EV-to-EBIT ratio for today is -1.73.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Regentis Biomaterials's Enterprise Value is $23.02 Mil.
Regentis Biomaterials's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.32 Mil. Therefore, Regentis Biomaterials's EV-to-EBITDA ratio for today is -1.73.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Regentis Biomaterials (AMEX:RGNT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Regentis Biomaterials's current Enterprise Value is $23.02 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.32 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Regentis Biomaterials's EV-to-EBITDA for today is:
Regentis Biomaterials's current Enterprise Value is $23.02 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-13.32 Mil.
Regentis Biomaterials's current Enterprise Value is $23.02 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.
Regentis Biomaterials's current Enterprise Value is $23.02 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil.
Regentis Biomaterials's current Enterprise Value is $23.02 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Regentis Biomaterials's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regentis Biomaterials Enterprise Value Related Terms
Regentis Biomaterials Enterprise Value Historical Data
* Premium members only.
The historical data trend for Regentis Biomaterials's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGNT vs MHUAF, LUCY, CUPR: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's Enterprise Value falls into.
Regentis Biomaterials Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Regentis Biomaterials's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regentis Biomaterials (RGNT) has a Enterprise Value of $23.02 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Enterprise Value too high?
Regentis Biomaterials' current Enterprise Value is $23.02 Mil. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Enterprise Value compare to MHUAF and LUCY?
Regentis Biomaterials' Enterprise Value of $23.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current Enterprise Value is $23.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Enterprise Value of $23.02 Mil. The current Enterprise Value is $23.02 Mil. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Enterprise Value is $23.02 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
